Publicacions en col·laboració amb investigadors/es de University of Texas MD Anderson Cancer Center (38)

2024

  1. Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma

    Cancer Epidemiology, Vol. 92

  2. How Molecular and Ancillary Tests Can Help in Challenging Cytopathology Cases: Insights from the International Molecular Cytopathology Meeting

    Journal of Molecular Pathology, Vol. 5, Núm. 2, pp. 228-237

  3. Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma

    OncoImmunology, Vol. 13, Núm. 1

2023

  1. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

    Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378

  2. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation

    ESMO Open, Vol. 8, Núm. 4

  3. Reference standards for gene fusion molecular assays on cytological samples: an international validation study

    Journal of clinical pathology, Vol. 76, Núm. 1, pp. 47-52

2022

  1. COVID-19 pandemic impact on cytopathology practice in the post-lockdown period: An international, multicenter study

    Cancer Cytopathology, Vol. 130, Núm. 5, pp. 344-351

  2. Editorial: Advances in Molecular Cytopathology

    Frontiers in Medicine

  3. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas

    JCI Insight, Vol. 7, Núm. 7

  4. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

    New England Journal of Medicine, Vol. 386, Núm. 26, pp. 2471-2481

2021

  1. Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET

    Clinical Cancer Research, Vol. 27, Núm. 6, pp. 1807-1820

  2. Elevated NSD3 histone methylation activity drives squamous cell lung cancer

    Nature, Vol. 590, Núm. 7846, pp. 504-508

2020

  1. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients with Osteosarcoma

    JAMA Oncology, Vol. 6, Núm. 5, pp. 724-734

  2. Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries

    Cancer Cytopathology, Vol. 128, Núm. 12, pp. 885-894

  3. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas

    Journal of Clinical Investigation, Vol. 130, Núm. 4, pp. 1879-1895

2019

  1. 5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging

    Thorax, Vol. 74, Núm. 4, pp. 371-379

  2. Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens

    Cancer Cytopathology, Vol. 127, Núm. 5, pp. 285-296

  3. Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network

    Cancer Research, Vol. 79, Núm. 3, pp. 625-638

  4. Tmprss4: A novel tumor prognostic indicator for the stratification of stage ia tumors and a liquid biopsy biomarker for nsclc patients

    Journal of Clinical Medicine, Vol. 8, Núm. 12

  5. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899